Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

Por Glaspy, J A, Jadeja, J S, Justice, G, Kessler, J, Richards, D, Schwartzberg, L, Tchekmedyian, N S, Armstrong, S, O'Byrne, J, Rossi, G, Colowick, A B
Publicado em 2002

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and...

Por Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M. E., Bondarenko, I., Sarosiek, T., Oprean, C., Cardona-Huerta, S., Lorusso, V., Karthaus, M., Schwartzberg, L., Grunberg, S.
Publicado em 2014

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a rand...

Por Higgins, M., Curigliano, G., Dieras, V., Kuemmel, S., Kunz, G., Fasching, P. A., Campone, M., Bachelot, T., Krivorotko, P., Chan, S., Ferro, A., Schwartzberg, L., Gillet, M., De Sousa Alves, P. M., Wascotte, V., Lehmann, F. F., Goss, P.
Publicado no Breast Cancer Res Treat (2017)

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

Por Glaspy, J, Jadeja, J Singh, Justice, G, Kessler, J, Richards, D, Schwartzberg, L, Rigas, J, Kuter, D, Harmon, D, Prow, D, Demetri, G, Gordon, D, Arseneau, J, Saven, A, Hynes, H, Boccia, R, O'Byrne, J, Colowick, A B
Publicado em 2001